image credit- shutterstock
GC Biopharma, a South Korean biopharmaceutical company, has signed a Memorandum of Understanding (MoU) with the Thai Red Cross Society (TRCS) to cooperate on workforce training for the production of plasma-derived medicinal products.
This MoU formalises and deepens a relationship that began in 2015, when GC Biopharma supported TRCS to establish a plasma fractionation facility in Thailand, and reflects the ongoing strategic collaboration between the two parties.
Under the terms of the MoU, GC Biopharma and TRCS will jointly develop and operate on-site training and exchange programmes for local production personnel. These programmes aim to transfer GC Biopharma's advanced manufacturing technologies and expertise to support the development of local capabilities.
In addition, both parties intend to continue identifying and expanding collaborative opportunities that align with their respective strengths and interests. The scope of cooperation will be gradually broadened to include potential joint projects such as the transfer of new processing technologies for plasma by-products and other strategic projects.
Meanwhile, GC Biopharma continues to expand its global plasma-derived therapeutics business. In addition to entering the US immunoglobulin market in 2024, the company is actively building partnerships in Southeast Asia, where domestic fractionation capabilities remain limited.
